- Home
- / Viridian Therapeutics
Viridian Therapeutics
Stock Price
$22.7
2024-10-29
Market Capitalization
$1.7 B
2024-10-29
Revenue
$70.8 M
FY, 2025
Viridian Therapeutics Summary
Company Summary
- Overview
- Viridian Therapeutics (formerly known as miRagen Therapeutics) is a biopharmaceutical company discovering and developing microRNA (miRNA)-targeting therapies. It offers expertise in miRNA biology, oligonucleotide chemistry, and drug development.
- Type
- Public
- Status
- Active
- Founded
- 2007
- HQ
- Waltham, MA, US | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Jennifer Tousignant, Chief Legal Officer
Thomas Ciulla, Chief Medical Officer
Seth Harmon, Senior Vice President of Finance and Accounting
LocationsView all
2 locations detected
Waltham, MA HQ
United States
221 Crescent St #401
Boulder, CO
United States
6200 Lookout Rd
Viridian Therapeutics Financials
Summary Financials
- Revenue (Q1, 2026)
- $141.0K
- Net income (Q1, 2026)
- ($104.9M)
- Cash (Q1, 2026)
- $762.2M
- EBIT (Q1, 2026)
- ($116.2M)
- Enterprise value
- $1.0B